Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2.

Trial Profile

Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2.

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2009

At a glance

  • Drugs NAPc2 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Nuvelo
  • Most Recent Events

    • 12 May 2009 Sponsor, affiliate and lead trial centre (ARCA Biopharma), lead investigator (Love T) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Primary outcome amended as reported by ClinicalTrials.gov.
    • 05 May 2008 The expected completion date for this trial is now 1 Aug 2007, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top